Search Results - "Sriramoju, Vindhya B"

Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting by Martin, Jesse, Williams, Alexis K., Klein, Melissa D., Sriramoju, Vindhya B., Madan, Shivanshu, Rossi, Joseph S., Clarke, Megan, Cicci, Jonathan D., Cavallari, Larisa H., Weck, Karen E., Stouffer, George A., Lee, Craig R.

“…Purpose To evaluate the frequency and clinical impact of switches in antiplatelet therapy following implementation of CYP2C19 genotyping after percutaneous…”
Get full text

Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention by Cavallari, Larisa H., Lee, Craig R., Beitelshees, Amber L., Cooper-DeHoff, Rhonda M., Duarte, Julio D., Voora, Deepak, Kimmel, Stephen E., McDonough, Caitrin W., Gong, Yan, Dave, Chintan V., Pratt, Victoria M., Alestock, Tameka D., Anderson, R. David, Alsip, Jorge, Ardati, Amer K., Brott, Brigitta C., Brown, Lawrence, Chumnumwat, Supatat, Clare-Salzler, Michael J., Coons, James C., Denny, Joshua C., Dillon, Chrisly, Elsey, Amanda R., Hamadeh, Issam S., Harada, Shuko, Hillegass, William B., Hines, Lindsay, Horenstein, Richard B., Howell, Lucius A., Jeng, Linda J.B., Kelemen, Mark D., Lee, Yee Ming, Magvanjav, Oyunbileg, Montasser, May, Nelson, David R., Nutescu, Edith A., Nwaba, Devon C., Pakyz, Ruth E., Palmer, Kathleen, Peterson, Josh F., Pollin, Toni I., Quinn, Alison H., Robinson, Shawn W., Schub, Jamie, Skaar, Todd C., Smith, D. Max, Sriramoju, Vindhya B., Starostik, Petr, Stys, Tomasz P., Stevenson, James M., Varunok, Nicholas, Vesely, Mark R., Wake, Dyson T., Weck, Karen E., Weitzel, Kristin W., Wilke, Russell A., Willig, James, Zhao, Richard Y., Kreutz, Rolf P., Stouffer, George A., Empey, Philip E., Limdi, Nita A., Shuldiner, Alan R., Winterstein, Almut G., Johnson, Julie A.

“…This multicenter pragmatic investigation assessed outcomes following clinical implementation of CYP2C19 genotype–guided antiplatelet therapy after percutaneous…”
Get full text

Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention by Lee, Craig R, Sriramoju, Vindhya B, Cervantes, Alexandra, Howell, Lucius A, Varunok, Nicholas, Madan, Shivanshu, Hamrick, Kasey, Polasek, Melissa J, Lee, John Andrew, Clarke, Megan, Cicci, Jonathan D, Weck, Karen E, Stouffer, George A

“…loss-of-function (LOF) alleles impair clopidogrel effectiveness after percutaneous coronary intervention. The feasibility, sustainability, and clinical impact…”
Get full text

THIRTY DAY CLINICAL OUTCOMES FOLLOWING IMPLEMENTATION OF CYP2C19 GENOTYPE-GUIDED DUAL ANTIPLATELET THERAPY by Klein, Melissa, Sriramoju, Vindhya B., Cervantes, Alexandra, Varunok, Nicholas, Madan, Shivanshu, Weck, Karen, Lee, Craig, Stouffer, George

“…The primary endpoint was major adverse ischemic cardiovascular or cerebral events (MACCE; death, acute coronary syndrome (ACS), stent thrombosis or…”
Get full text

Multi-site Investigation of Outcomes with Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy after Percutaneous Coronary Intervention by Cavallari, Larisa H., Lee, Craig R., Beitelshees, Amber L., Cooper-DeHoff, Rhonda M., Duarte, Julio D., Voora, Deepak, Kimmel, Stephen E., McDonough, Caitrin W., Gong, Yan, Dave, Chintan V., Pratt, Victoria M., Alestock, Tameka D., Anderson, R. David, Alsip, Jorge, Ardati, Amer K., Brott, Brigitta C., Brown, Lawrence, Chumnumwat, Supatat, Clare-Salzler, Michael J., Coons, James C., Denny, Joshua C., Dillon, Chrisly, Elsey, Amanda R., Hamadeh, Issam, Harada, Shuko, Hillegass, William B., Hines, Lindsay, Horenstein, Richard B., Howell, Lucius A., Jeng, Linda J.B., Kelemen, Mark D., Lee, Y.M., Magvanjav, Oyunbileg, Montasser, May, Nelson, David R., Nutescu, Edith A., Nwaba, Devon C., Pakyz, Ruth E., Palmer, Kathleen, Peterson, Josh F., Pollin, Toni I., Quinn, Alison H., Robinson, Shawn W., Schub, Jamie, Skaar, Todd C., Smith, Donald M., Sriramoju, Vindhya B., Starostik, Petr, Stys, Tomasz P., Stevenson, James M., Varunok, Nicholas, Vesely, Mark R., Wake, Dyson T., Weck, Karen E., Weitzel, Kristin W., Wilke, Russell A., Willig, James, Zhao, Richard Y., Kreutz, Rolf P., Stouffer, George A., Empey, Philip E., Limdi, Nita A., Shuldiner, Alan R., Winterstein, Almut G., Johnson, Julie A.

Get full text

Abstract 16889: Risk Factors for Bleeding Modify the Impact of CYP2C19 Genetic Test Results on Antiplatelet Drug Selection by Sriramoju, Vindhya B, Varunok, Nicholas, Howell, Lucius A, Cervantes, Alexandra, Polasek, Melissa J, Stouffer, George A, Lee, Craig R

“…IntroductionOur institution uses CYP2C19 genotype to enhance precision of antiplatelet drug selection in high risk patients following percutaneous coronary…”
Get full text